Mutations in EZH2, particularly gain-of-function (GOF) mutations, have been identified in a variety of malignancies, including lymphomas, breast cancer, and prostate cancer [57–60], and frequently occur in the EZH2 SET domain [52–55]. This evidence concerns the gene EZH2 and Familial prostate cancer.